MedTech Industry Strategic Interest Areas 2023

All device, diagnostic, and digital startups are encouraged to apply to MedTech Innovator at Additionally, the following list highlights technologies identified as specifically of strategic interest via our medtech industry survey. 


Disrupts an existing drug market with an unmet need

  • Applications: heart failure, COPD, peripheral artery disease, vascular disease, AFIB, structural heart conditions, ECMO

Interventional tools

  • Applications: radiology, pulmonology, vascular, neurovascular, stroke treatment

Minimally invasive surgical tools

  • Robotic tools for endoluminal surgeries: GI tract, vascular, biopsies, surgical oncology
  • Digital surgery
  • Energy (laparoscopic)
  • Cryoablation tools and techniques

Biocompatible materials

  • Promotes wound healing
  • MRI-compatible
  • 3D printable
  • Anti-microbial
  • Applications: hernia repair, catheters


  • Flexible modalities
  • Navigation
  • Energy
  • Applications: GI, pancreas, pulmonology, ENT

Innovative safety mechanisms

  • Renal/dialysis products
  • Injection, infusion, and transfusion devices
  • Needleless and safety connector systems

Automated cell culture equipment and systems

  • Stem cell growth systems
  • Serum-free culture
  • 3D organ culture
  • Applications: cell therapy


  • AR / VR
  • Biosensors
  • IOL
  • Correction of visual access
  • Diagnostics
  • Modalities when central retina is destroyed
  • Patient education
  • Self-monitoring of biometric and health behavior parameters
  • Improved management of chronic diseases with severe comorbidities and predictive analytics
  • Non-drug pain management solutions
  • Patient empowerment tools for improved self-care


Measure relevant biometric & behavior parameters

  • Risk prevention and mitigation for efficient care and timely intervention
  • Patient stratification / identifying populations
  • Patient status management: nutrition, fluids, etc.
  • Chronic disease management: heart failure, diabetes, obesity, metabolic diseases
  • Sensors, wearables, implantables
    • Semiconductor-enabled
    • Non-invasive or minimally invasive
    • BP, ECG, hydration, sweat, temperature, fluid status, metabolites
    • Application: opioid overdose, fluid monitoring

  • Medication delivery, tracking & adherence
  • Telemedicine/teleconsultation
  • Hospital inventory management: asset tracking (e.g. RFID)


With/without clinical decision support

  • Novel osteoporosis diagnostics
  • Diabetes mitigation & management
  • Rapid infectious diseases diagnostics
    • Molecular diagnostics for virus/flu

  • Narrow-band imaging
  • Advanced imaging for GI

  • Infection prevention and treatment: surgery and orthopedics
  • Global health
  • Sleep apnea
  • Organ support
  • Biomarkers


MedTech Innovator was selected by BARDA to accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats. If you know a company that matches the interests below, please encourage them to email and apply at and reference MedTech Innovator as the source of the application.


Sepsis is one of the country’s most urgent systemic health threats. Each year, more than 1.5 million people in the U.S. get sepsis. Sepsis kills a quarter-million Americans each year. Sepsis can occur when a trauma or an infection – often caused by a superbug or drug-resistant bacteria in the skin, lungs or kidney (urinary tract) – triggers a chain reaction throughout the body. Without timely recognition and treatment, it can rapidly cause tissue damage, organ failure, and death. One in three patients who die in a hospital have sepsis. Read more about sepsis.

DRIVe is seeking bold solutions to solve sepsis. These include innovations focused on:

  • Clinical management strategies supported by enhanced education and awareness
  • Rapid diagnostics & prognostics
  • Continuous multi-dimensional patient monitoring
  • Machine learning-based disease management feedback algorithms
  • Optimized therapeutic interventions

Too often, people do not receive adequate and timely treatment for infectious diseases like influenza. We either do not seek care, or do so many days late, leading to severe illness, and transmission of infectious agents within the household, at the workplace. Early Notification to Act, Control, and Treat (ENACT) will disrupt the traditional clinical care paradigm of healthcare outside of the home (within a physician’s office, urgent care center, or hospital). It will rapidly leverage the power of transformational technologies to empower individuals to be aware of their own health status and to take action.

DRIVe seeks solutions that:

  • Develop noninvasive wearable and on-demand physiological and biomarker detectors that monitor physiological changes from the user’s baseline
  • Identify robust algorithms that analyze the resulting clinical data and detect health and illness signatures
  • Develop software platforms capable of detection changes in individual and population-wide health status
  • Identify the key markers of health status for enabling high-accuracy presymptomatic detection of infection


MedTech Innovator is sourcing opportunities in partnership with US military. The following list highlights technologies identified as specifically of interest by the US Military for this event. If you know a company that matches any of these interest areas, then please encourage them to apply at


  • Direct retinal displays
  • Volumetric holography – military medical use
  • Neuro haptics & haptics technology
  • Immersive holodeck & immersion teaching tools
  • Robotic medical patient surrogates
  • Tools to improve learning effectiveness, memory & retention, cognitive performance
  • Empathy generators – live, virtual, augmented reality
  • Nanosensors & communication
  • 3D nanoprinting & novel inks
  • Human-machine interface – medical focus
  • Wearable technology to detect physiological or host biomarkers as predictive and prognostic indicators of infection-induced sepsis
  • Safe and efficacious interventions to be utilized at the point of injury for eradication of bacterial pathogens from contaminated wounds and inhibition/disruption of biofilms formed by MDR pathogens. Examples of target wound-associated bacteria are: Acinetobacter baumannii, Staphylococcus aureus, E. coli, and Klebsiella pneumoniae
  • A broad spectrum anti-viral that provides Warfighters durable immunity and protection from naturally occurring endemic infectious diseases

Artificial intelligence for real-time medical command awareness in multi-domain operations

  • Use of AI tools and techniques to automate medical documentation (EHR and other clinical information)
  • Use of AI in clinical decision support to enable remote provision of care and for improved patient safety/monitoring

Technology Objectives: The Clinical and Rehabilitative Medicine Research Program has identified a need for regenerative medicine prototype development efforts and manufacturing technologies. Current Good manufacturing practice (cGMP) quality is a requirement by the FDA and European Medicines Agency to provide patients with clinical-grade products that are safe and have defined quality characteristics. However, standardization and robust manufacturing techniques are lacking in regenerative medicine, which will continue to impede progress in advancing regenerative medicine based technologies and treatments toward the clinic. This is likely due to many factors which need to be developed and advanced, including 1) Processing technologies for Quality Management of acellular matrices or Stem Cell (SC)-derived cell based therapies. 2) Manufactured Universal Acellular Matrix 2) Innovative Manufacturing Process for SC-Derived Cell Based Therapies. Based on this, the major objective of this effort is to develop solutions for quality management of prototypes and processes for cell, tissue, or organ bioengineering technologies that will overcome current challenges and enable successful cGMP manufacturing and clinical translation of regenerative medicine based therapies.

Technologies of interest include the following:

    • Processing technologies for quality assurance of acellular matrices or SC-derived cell based therapies (assurance, control, or quality testing)
    • Manufactured universal acellular matrix
    • Innovative manufacturing process for stem cell (SC)-derived cell based therapies
  • Wearable, on-demand device for the management of symptoms associated with PTSD that is efficacious in a military or veteran population
  • Guidelines on the implementation of human-automation teaming that optimizes human performance and increases operational effectiveness
  • Injury risk model for the brain and spine when the whole body is subjected to potentially hazardous acceleration/deceleration loads from military relevant exposures
  • Brain injury risk model, test methodology, and assessment tool that can output probability of brain injury risk resulting from single and repetitive blast exposures
  • Medically-based performance requirements that can provide behind helmet blunt trauma survivability and brain injury risk curves for helmets exposed to current and emerging ballistic threats
  • Whole body blast injury criteria to evaluate the next generation bomb suit and body armor blast personal protection equipment
  • An efficient and effective method for personalized training to build and enhance cognitive/brain health, performance and psychological health
  • Individual training modalities and thermal models that reduce cold-weather injuries and improve cold weather performance
  • Models that quantify impacts of glymphatic/lymphatic clearance in the brain on short-term impacts on the restorative effects of sleep
  • Limitation of burn conversion and burn treatments
  • Non-compressible hemorrhage
  • Supplemental and therapeutic oxygen